-
Je něco špatně v tomto záznamu ?
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
M. Ducreux, GK. Abou-Alfa, T. Bekaii-Saab, J. Berlin, A. Cervantes, T. de Baere, C. Eng, P. Galle, S. Gill, T. Gruenberger, K. Haustermans, A. Lamarca, P. Laurent-Puig, JM. Llovet, F. Lordick, T. Macarulla, D. Mukherji, K. Muro, R. Obermannova,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
Grantová podpora
P30 CA008748
NCI NIH HHS - United States
NLK
Directory of Open Access Journals
od 2016
PubMed Central
od 2016
Europe PubMed Central
od 2016
Open Access Digital Library
od 2016-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2016
- MeSH
- gastrointestinální nádory * diagnóza terapie MeSH
- hepatocelulární karcinom * diagnóza terapie MeSH
- lidé MeSH
- nádory jater * diagnóza terapie MeSH
- znalecký posudek MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.
Aichi Cancer Center Hospital Nagoya Japan
American University of Beirut Beirut Lebanon
BC Cancer University of British Columbia Vancouver Canada
Clinica Universidad de Navarra and CIBEREHD Pamplona Spain
Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Medical Oncology The Christie NHS Foundation Manchester
Department of Oncology OncoHealth Institute Fundación Jiménez Díaz University Hospital Madrid Spain
Division of Cancer Sciences University of Manchester Manchester UK
Hammersmith Hospital Imperial College London London UK
Icahn School of Medicine at Mount Sinai Mount Sinai Liver Cancer Program New York USA
Institució Catalana de Recerca i Estudis Avançats Barcelona Spain
Institut du cancer Paris CARPEM APHP Georges Pompidou Hospital Université Paris Cité Paris France
Institute of Oncology IOB Quiron UVic UCC Barcelona Spain
Instituto Alexander Fleming Buenos Aires Argentina
Instituto Nacional de Cancerologia Mexico Mexico
Karolinska University Hospital Karolinska Institutet Stockholm Sweden
Katholieke Universiteit Leuven Leuven Belgium
Masaryk Memorial Cancer Institute Faculty of Medicine Masaryk University Brno Czech Republic
Mayo Clinic Cancer Center Phoenix
Memorial Sloan Kettering Cancer Center New York
Tampere University Hospital University of Tampere Tampere Finland
Trinity College Dublin Dublin Ireland
Ulm University Hospital Ulm Germany
Université Paris Saclay Gustave Roussy Villejuif France
University Hospitals Gasthuisbergs Leuven
University Medical Center Mainz Mainz Germany
University of Leipzig Medical Center Comprehensive Cancer Center Central Germany Leipzig Germany
Vall d'Hebron Hospital Campus and Institute of Oncology IOB Quiron UVic UCC Barcelona Spain
Vall d'Hebron Hospital Campus Barcelona Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23017072
- 003
- CZ-PrNML
- 005
- 20231026105425.0
- 007
- ta
- 008
- 231013s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.esmoop.2023.101567 $2 doi
- 035 __
- $a (PubMed)37263081
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Ducreux, M $u Université Paris-Saclay, Gustave Roussy, Villejuif, France. Electronic address: michel.ducreux@gustaveroussy.fr
- 245 14
- $a The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022 / $c M. Ducreux, GK. Abou-Alfa, T. Bekaii-Saab, J. Berlin, A. Cervantes, T. de Baere, C. Eng, P. Galle, S. Gill, T. Gruenberger, K. Haustermans, A. Lamarca, P. Laurent-Puig, JM. Llovet, F. Lordick, T. Macarulla, D. Mukherji, K. Muro, R. Obermannova, JM. O'Connor, EM. O'Reilly, P. Osterlund, P. Philip, G. Prager, E. Ruiz-Garcia, B. Sangro, T. Seufferlein, J. Tabernero, C. Verslype, H. Wasan, E. Van Cutsem
- 520 9_
- $a This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a hepatocelulární karcinom $x diagnóza $x terapie $7 D006528
- 650 12
- $a nádory jater $x diagnóza $x terapie $7 D008113
- 650 _2
- $a znalecký posudek $7 D005104
- 650 12
- $a gastrointestinální nádory $x diagnóza $x terapie $7 D005770
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Abou-Alfa, G K $u Memorial Sloan Kettering Cancer Center, New York; Weill Cornell College of Medicine, New York, USA; Trinity College Dublin, Dublin, Ireland
- 700 1_
- $a Bekaii-Saab, T $u Mayo Clinic Cancer Center, Phoenix
- 700 1_
- $a Berlin, J $u Vanderbilt-Ingram Cancer Center, Nashville, USA
- 700 1_
- $a Cervantes, A $u INCLIVA, Biomedical Research Institute, Hospital Clínico Universitario, University of Valencia, Valencia, Spain
- 700 1_
- $a de Baere, T $u Université Paris-Saclay, Gustave Roussy, Villejuif, France
- 700 1_
- $a Eng, C $u Vanderbilt-Ingram Cancer Center, Nashville, USA
- 700 1_
- $a Galle, P $u University Medical Center Mainz, Mainz, Germany
- 700 1_
- $a Gill, S $u BC Cancer/University of British Columbia, Vancouver, Canada
- 700 1_
- $a Gruenberger, T $u Clinic Favoriten, HPB Center Health Network Vienna and Sigmund Freud University, Medical School, Vienna, Austria
- 700 1_
- $a Haustermans, K $u University Hospitals Gasthuisbergs, Leuven; Katholieke Universiteit Leuven, Leuven, Belgium
- 700 1_
- $a Lamarca, A $u Department of Oncology, OncoHealth Institute, Fundación Jiménez Díaz University Hospital, Madrid, Spain; Department of Medical Oncology, The Christie NHS Foundation, Manchester; Division of Cancer Sciences, University of Manchester, Manchester, UK
- 700 1_
- $a Laurent-Puig, P $u Institut du cancer Paris CARPEM, APHP, Georges Pompidou Hospital, Université Paris Cité, Paris, France
- 700 1_
- $a Llovet, J M $u Icahn School of Medicine at Mount Sinai, Mount Sinai Liver Cancer Program, New York, USA; Institut d'Investigacions Biomèdiques August Pi i Sunyer Hospital Clínic, Universitat de Barcelona, Barcelona; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain
- 700 1_
- $a Lordick, F $u University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany, Leipzig, Germany
- 700 1_
- $a Macarulla, T $u Vall d'Hebron Hospital Campus, Barcelona, Spain; Institute of Oncology, IOB-Quiron, UVic-UCC, Barcelona, Spain
- 700 1_
- $a Mukherji, D $u American University of Beirut, Beirut, Lebanon
- 700 1_
- $a Muro, K $u Aichi Cancer Center Hospital, Nagoya, Japan
- 700 1_
- $a Obermannova, R $u Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a O'Connor, J-M $u Instituto Alexander Fleming, Buenos Aires, Argentina
- 700 1_
- $a O'Reilly, E M $u Memorial Sloan Kettering Cancer Center, New York; Weill Cornell College of Medicine, New York, USA
- 700 1_
- $a Osterlund, P $u Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; Tampere University Hospital, University of Tampere, Tampere, Finland
- 700 1_
- $a Philip, P $u Henry Ford Cancer Institute, Departments of Oncology and Pharmacology, Wayne State University, Detroit, USA
- 700 1_
- $a Prager, G $u Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Ruiz-Garcia, E $u Instituto Nacional de Cancerologia, Mexico, Mexico
- 700 1_
- $a Sangro, B $u Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain
- 700 1_
- $a Seufferlein, T $u Ulm University Hospital, Ulm, Germany
- 700 1_
- $a Tabernero, J $u Vall d'Hebron Hospital Campus and Institute of Oncology, IOB-Quiron, UVic-UCC, Barcelona, Spain
- 700 1_
- $a Verslype, C $u University Hospitals Gasthuisbergs, Leuven; Katholieke Universiteit Leuven, Leuven, Belgium
- 700 1_
- $a Wasan, H $u Hammersmith Hospital, Imperial College London, London, UK
- 700 1_
- $a Van Cutsem, E $u University Hospitals Gasthuisbergs, Leuven; Katholieke Universiteit Leuven, Leuven, Belgium
- 773 0_
- $w MED00196632 $t ESMO open $x 2059-7029 $g Roč. 8, č. 3 (2023), s. 101567
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37263081 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105420 $b ABA008
- 999 __
- $a ok $b bmc $g 2000546 $s 1203434
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 8 $c 3 $d 101567 $e 20230531 $i 2059-7029 $m ESMO open $n ESMO Open $x MED00196632
- GRA __
- $a P30 CA008748 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20231013
